Roche attributes a $3.83 billion reduction in sales to biosimilar competition.
Biosimilar competition for Roche added up to a $3.83 billion reduction in sales in the first 9 months of 2020, contributing to a sales decline of 4% in the United States for the pharmaceutical giant.
Roche had a 1% overall decrease in pharmaceutical sales, stating that the coronavirus disease 2019 (COVID-19) pandemic also had a significant effect on revenues for the 9-month period.
Roche markets the originator products Avastin (bevacizumab), Rituxan (rituximab), and Herceptin (trastuzumab), each of which faces international biosimilar competition. In the United States, Roche saw increased sales of Ocrevus (ocrelizumab), Hemlibra (emicizumab), Tecentriq (atezolizumab), Actemra/RoActemra (tocilizumab), and Kadcycla (ado-trastuzumab emtansine); however, the US revenues from these products were offset by biosimilar competition, the company noted.
US pharmaceutical sales dropped to $20.1 billion from $21.9 billion for the first 9 months of 2020, an 8% decrease. Japan sales dropped to $3.0 billion from $3.4 billion, a 9% drop. In Europe, sales dropped $6.85 billion vs $6.90 billion, a 1% decrease.
In Europe, Roche’s sales of trastuzumab, bevacizumab, and rituximab declined 32%, 16%, and 32%, respectively. The company largely attributed the drop to biosimilars.
Sales also decreased 6% in Japan “as a result of the considerable competition from biosimilars, generics, COVID-19, and government price cuts,” the company said.
Overall sales erosion from biosimilars was 22% for Avastin, 27% for Rituximab, and 31% for Herceptin. Roche reported strong worldwide sales gains for new products expected to compensate for biosimilar competition, such as Tecentriq, up 64%; Ocrevus, up 29%; Hemlibra, up 79%; and Actemra/RoActemra, up 33%.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.